Does maternal MDR1 C1236T polymorphism have an effect on placental arsenic levels?

AKYÜZLÜ D., Kayaalti Z., Dogan D., Soylemezoglu T.

ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, vol.41, pp.142-146, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 41
  • Publication Date: 2016
  • Doi Number: 10.1016/j.etap.2015.11.019
  • Journal Name: ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.142-146
  • Keywords: Arsenic, Phospho-glycoprotein (P-gp), Human multidrug resistance 1 (MDR1), MDR1 C1236T polymorphism, Placental tissue, DOUBLE KNOCKOUT MICE, P-GLYCOPROTEIN, EXPRESSION, GENE, POPULATION, EXPOSURE, ABCB1
  • Ankara University Affiliated: Yes

Abstract

To detect whether maternal MDR1 C1236T polymorphism has an effect on placental arsenic levels, 112 mother-placenta pairs were examined. Venous blood samples from mothers were collected to investigate the C1236T polymorphism which was detected by standard PCR-RFLP technique. Placentas were collected to measure arsenic levels by GF-AAS. The MDR1 C1236T genotype frequencies of mothers were found as 30.3% homozygote typical (CC), 51.8% heterozygote (CT) and 17.9% homozygote atypical (TT). The mean placental arsenic level was 62.36 +/- 30.43 mu g/kg. It was observed that the placental arsenic concentrations were higher in mothers with TT genotype than those with CC and a genotypes, but this was not statistically significant (p = 0.702). This finding was indicated that fetuses of mothers with TT genotype may be more susceptible to arsenic toxicity as compared to those of with CC and CT genotypes. We believe that this difference warrant further studies with larger study subjects. (C) 2015 Elsevier B.V. All rights reserved.